
CVSA Stock Forecast & Price Target
CVSA Analyst Ratings
Bulls say
Covista is well-positioned to benefit from labor shortages and upskilling trends in the healthcare industry, with strong enrollment in clinical fields and a focus on profitable expansion. The company has a discounted valuation and limited exposure to new loan policies, and is expected to see 14% upside to EPS consensus in FY28. With a strong base in healthcare education and potential for growth in the future, Covista's shares have potential for growth despite potential challenges in expanding through acquisitions.
Bears say
Covista is facing a number of challenges that could negatively impact its stock performance. These include softer new start growth at its Chamberlain campus, concerns around its financial responsibility score, potential regulatory challenges, and decreased demand for for-profit education. Additionally, the company's recent executive leadership changes and potential competition in the increasingly competitive online education market could also pose risks. Despite potential upside from improved Chamberlain enrollment and attractive valuation, these factors lead to a negative outlook for the company's stock.
This aggregate rating is based on analysts' research of Adtalem Global Education Inc and is not a guaranteed prediction by Public.com or investment advice.
CVSA Analyst Forecast & Price Prediction
Start investing in CVSA
Order type
Buy in
Order amount
Est. shares
0 shares